NFATC2 and sarcoma: Pathway analysis identified a significant activation of the mTOR pathway in EWSR1-NFATc2 positive sarcomas compared to either EWSR1-ETS or CIC-DUX4 positive sarcomas (EWSR1-NFATc2 vs. EWSR1-ETS: z-score = 1.6, p = 0.002; EWSR1-NFATc2 vs. CIC-DUX4: z-score = 1, p < 0.001; Supplementary Fig. 2C, D).